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New Strategy for Overcoming Resistance to Chemotherapy of Ovarian Cancer
Junzo Kigawa 
Tottori University Hospital Cancer Center, Yonago 683-8504, Japan
The incidence of ovarian cancer in 2008 was projected 
to be 225,500 new cases and 140,200 deaths worldwide, 
representing 3.7% of all female cancers and 4.2% of all 
cancer deaths in women.1 Ovarian cancer, one of the 
major causes of death from cancer in women, is com-
monly diagnosed at advanced stage. Cytoreductive 
surgery followed by platinum and taxane-based combi-
nation chemotherapy is currently the standard treatment 
for ovarian cancer.2 Ovarian cancer is one of the most 
sensitive solid tumors, with objective responses ranging 
from 60 to 80% even in patients with advanced stage.3 
However, most patients ultimately recur and develop 
chemo-resistance. 
 An international study, GOG 182-ICON 5, sought to 
improve the efficacy of standard platinum-taxane thera-
py by incorporating newer cytotoxic agents (gemcitabine, 
pegylated liposomal doxorubicin and topotecan).4 Un-
fortunately, the combination of these agents used in 
standard therapy has not improved overall survival (OS). 
Furthermore, the most effective regimen for second line 
chemotherapy has not yet been determined. The second 
line chemotherapies have achieved objective responses 
in about 10 to 30% of patients and even lower percent-
age of complete response.5 As a result, the survival rate 
for patients with ovarian cancer has not improved over 
the past 20 years.6 A new strategy is needed to improve 
the prognosis of patients with ovarian cancer.
 Resistance to chemotherapy presents a major ob-
stacle to attempt to improve the prognosis of patients 
with ovarian cancer. Accordingly, it is important for the 
management of ovarian cancer to elucidate the mecha-
nisms of chemoresistance and to get over the resistance. 
Recently, the biological characteristics of ovarian cancer 
have been clear and molecular-targeted agents including 
signal-transduction inhibitors and anti-angiogenesis have 
developed. Here, a new strategy for treatment of ovarian 
cancer is discussed from the viewpoint of the conquest 
of chemoresistance based on our data.  
 
CHEMORESISTANCE MECHANISMS AND 
SECOND LINE CHEMOTHERAPY
Anticancer drugs interfere indiscriminately with DNA 
synthesis, DNA repair systems and mitosis. Many mech-
anisms have been postulated to explain chemoresistance, 
including decreased drug accumulation inside tumor 
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cells, increased cellular detoxification and increased 
DNA repair activity.7, 8, 9 Apoptosis and survival signal 
pathway also contribute to sensitivity to anti-cancer 
agents10, 11 (Fig. 1). Platinum and taxane agents are key 
drugs for first line chemotherapy of ovarian cancer.3 
Second line chemotherapy should be chosen in consider-
ation of chemoresistance mechanisms. 
 Platinum agent such as cisplatin (CDDP) is one of 
the most active anticancer agents now used.  The length 
of the progression free interval following the first plati-
num-based chemotherapy is the most important predic-
tive factor of response to second line chemotherapy.12, 13, 
14, 15 The patients who relapse after over 24 months have 
the highest chance of responding to the first platinum-
based chemotherapy. In contrast, patients who recur 
within 6 months show low response rate.13 
 Despite its broad clinical applications, however, in-
trinsic or acquired resistance to CDDP often culminates 
in chemotherapeutic failure. Of the several approaches 
used to overcome the resistance to CDDP, the use of 
other drugs given in combination seems to be essential. 
Experimental studies on the combined effects of CDDP 
and other anticancer agents can provide information on 
the most appropriate sequence. 
 Multidrug resistance-associated protein (MRP) 
gene functions as an ATP-dependent pump for cytotoxic 
drugs and MRP plays the significant role for platinum 
resistance in ovarian cancer.8 Interestingly, topoisom-
erase (topo) I enzymatic activity was 2- to 4-fold higher 
in the CDDP-resistant cell lines compared with their 
respective parent cell lines. Additionally, topo II protein 
contents in resistant ovarian cancer cells were signifi-
cantly greater compared with those of their parent cell 
lines.11 It is reported that the expression levels of topoi-
somerase were associated with sensitivity to topoisomer-
ase inhibitors.16, 17
 DNA topo inhibitors are of interest as targets for 
cancer chemotherapy.18 7-Ethyl-10-[4-(1-piperidino)-
1-piperidino] carbonyloxycamptothecin (CPT-11) inhib-
its topo I through the formation of stable topo I-DNA 
cleavable complexes.19 CPT-11, a semisynthetic water-
soluble derivative of camptothecin, has a potent antitu-
mor activities.19 CPT-11 is known as an effective against 
pleiotropic drug-resistant tumors in vitro and in vivo and 
shows some lack of cross resistance with CDDP.20, 21, 22, 
23 Furthermore, the synergism between CDDP and CPT-
11 has been demonstrated and clinical studies showed 
that the CPT-11/CDDP combination was more effica-
cious than CPT-11 alone.24
 KF cells, epithelial ovarian carcinoma cell line and 
a CDDP resistant subline, KFr were used as an acquired 
CDDP-resistant model. The effects of CDDP in com-
bination with SN-38, an active metabolite of CPT-11, 
on KF and KFr cells were analyzed using an improved 
isobologram method (Fig. 2).  For KF cells, the com-
bined data points fell within an envelope surrounded 
by three lines, indicating an additive effect. In contrast, 
for KFr, CDDP-resistant cell line, the data points were 
below the envelopes, indicating a supra-additive (syner-
gistic) effect. These results suggest that the combination 
of CDDP and SN-38 may be more effective in CDDP-
resistant cells than in the parent cells. To determine the 
biological factors involved in the sensitivity to the com-
bination of CDDP and SN-38, we compared topo I cata-
lytic activity between KF and KFr cells (Fig. 3). Topo I 
activity in KFr was greater than in KF cells; the increase 
was 4-fold for KFr cells versus KF cells. A potential 
mechanism to explain the synergism between CDDP 
and topo I inhibitors has been proposed; an increased 
DNA interstrand cross-linking by the simultaneous 
exposure to CDDP and topo I inhibitor and an enhance-
ment of the activity of topo I inhibitors by high doses of 
CDDP.25 Although these findings do not explain why the 
enhancement of CDDP cytotoxicity by a topo I inhibitor 
was observed only in the CDDP-resistant cells, the en-
hanced topo I activity could, at least in part, contribute 
Fig. 1. Many mechanisms of anticancer 
agents have been proposed, including 
decreased drug accumulation, increased 
cellar detoxification by proteins such as 
glutathione, decreased the induction of 
apoptosis and increased DNA repair. 
GCS, glutamylcysteine synthetase; 
GSH, glutathione; MDR-l, multidrug-
resistance-1; MRP, multidrug resistance-
associated protein.
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to the enhancement of CDDP cytotoxicity in CDDP-re-
sistant cells more effectively than in the parent cells. Ad-
ditionally, a significant correlation between the sensitiv-
ity for SN-38 and topo I activity was observed. Fukuda 
et al. demonstrated that the sensitivity of tumor cells to 
topo I inhibitors was associated with intracellular topo 
I level.26 Topo I expression reflects sensitivity to topo I 
inhibitor.26, 27 Hochster et al.27 found a negative correla-
tion of topo I protein level with area under the curve of 
topo I inhibitor, and Subramanian et al.28 demonstrated 
that topo I activity measured by ICE bioassay related to 
response to topo I inhibitor. Those findings including 
our study mentioned above suggest topo I activity may 
be a useful predictor of resistance or sensitivity to CPT-
11 based chemotherapy. 
 Next, we examined the relationship between topo I 
activity and the sensitivity to chemotherapy consisting of 
CDDP and CPT-11 in patients with relapsed ovarian can-
cer.29 A total of 30 subjects were selected from patients 
for recurrent epithelial ovarian cancer with measurable 
lesions. All patients had initially undergone platinum-
based chemotherapy. All patients underwent surgery to 
remove recurrent tumor before second line chemothera-
py consisting of CPT-11 and CDDP, but did not receive 
complete resection. Tumor samples were obtained at the 
surgery. All patients received 50 to 60 mg/m2 CPT-11 
intravenously over a 90-min period on days 1, 8 and 15. 
Additionally, 60 mg/m2 CDDP was infused intravenous-
ly over a 120- min period on day 1. Of the 30 patients, 
18 responded to CPT-11 and CDDP (complete response 
= 2; partial response = 16) and 12 did not (no change = 
8; progressive disease = 4). There were no significant 
differences in patient characteristics and performance 
status between the responders and the nonresponders to 
the second line chemotherapy. The minimum amount of 
extracted nuclear protein after platinum-based chemo-
therapy showing complete DNA relaxation ranged from 
15 to 388 ng. The amount of nuclear protein required for 
complete DNA relaxation was significantly greater in 
responders than in nonresponders (201.7 ± 92.5 versus 
124.1 ± 59.4 ng, P = 0.0164; Fig. 4). This result reflects 
our in vitro finding that topo I activity was enhanced 
by exposure to CDDP and related to chemosensitivity. 
Therefore, the combination chemotherapy consisting of 
CPT-11 and CDDP may be an effective second line che-
motherapy for CDDP resistant ovarian cancer. 
 
 
GENETIC DIAGNOSIS fOR CHEMOSENSITIv-
ITY wITH DRuG-RESISTANCE GENES
In previous chemosensitivity assays, cancer cells were 
isolated from the tumor, and these cultured cells were 
exposed to chemotherapeutic agents for evaluating the 
effectiveness of agents. The assays are complex and dif-
Fig. 3. Topo I catalytic activity 
in KF and KFr cells. Topo I 
catalytic activity in KFr cells 
is 4-fold of that in KF cells. 
KFr, cisplatin-resistant KF; 
topo, topoisomerase.
 
Fig. 2. Isobolograms of cisplatin (CDDP) 
at IC50, based on dose response curves in 
combination with SN-38 in KF and KFr 
cell lines. The abscissa shows the ratio of 
concentration to the IC50 for CDDP, and 
the ordinate represents that for SN-38. 
The solid line represents mode I, and the 
two broken lines represent mode II. The 
exposure of CDDP combined with SN-38 
to KF cells produces only additive effects. In contrast, for KFr cells the combination of CDDP and SN-38 is syner-
gistic. IC50, half maximal inhibitory concentration; KFr, cisplatin-resistant KF.
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ficult. In contrast, genetic diagnosis for chemosensitivity 
is more convenient because cell culture is unnecessary 
and the transportation of specimen is easy for genetic 
diagnosis. cDNA microarray analysis of non-small cell 
lung cancers after laser-capture microdissection of can-
cer cells from primary tumors, showing a significant as-
sociation between expression levels of genes and chemo-
sensitivity.30 The reference of the gene, which is peculiar 
to each anticancer agent, may be useful in determining 
sensitivity.  
 Although chemoresistance is a multifactorial phe-
nomenon, on the occasion of the clinical application, 
several candidate agents must be tested and validated on 
small specimens of the patient’s tumor to select effective 
agents for that individual. Accordingly, it is important to 
limit the number of examined genes for the cost benefit 
on the occasion of the clinical application. Anticancer 
agents against epithelial ovarian cancer are still limited 
to a few drugs, such as platinum agents, taxane com-
pounds and DNA topoisomerase inhibitors. 
 The expression of multidrug-resistance-1 (MDR-
1) gene encoding P-glycoprotein gene was significantly 
higher in non-responders of taxane and carboplatin 
therapy.31 Due to the hydrophilic nature of taxane com-
pound, resistance to taxane agent is associated with 
MDR-1. MDR-1 gene expression is related to sensitivity 
to taxane compounds in ovarian cancer.32 In contrast, 
there were no differences in the level of MRP between 
responders and non-responders prior to chemotherapy.8 
After chemotherapy, however, MRP gene expression 
was significantly higher in non-responders than in re-
sponders. MRP gene expression, at least before chemo-
therapy, may not relate to chemoresponse. MDR-1 gene 
might be a useful predictor for combination taxane and 
carboplatin therapy. 
 Copy number of topo I gene inversely correlated 
with sensitivity to SN38. Additionally, the expression 
levels of topo I were lower in CPT-resistant cell lines, 
and the expression levels of topo IIalpha were lower in 
etoposide-resistant cell lines than in their parent cell 
lines that contained fewer copies than their parent cells. 
The expression of topo I was significantly higher in CPT-
11/CDDP responders and topo IIalpha was also higher 
in etoposide responders, suggesting that the expression 
level of topoisomerase contributes to sensitivity to topoi-
somerase inhibitor.31  
 As a result, the accuracy of the present genetic diag-
nosis for chemosensitivity was 85.7 % for taxane/carbo-
platin therapy, 77.8% for etoposide /cisplatin and 100.0% 
for CPT-11/CDDP therapy.  
 
MOLECuLAR-TARGETED THERAPY 
Recent advances in our understanding of the molecular 
biology of cancer and carcinogenesis have led to a vari-
ety of targeted agents. Targeted agents affect tumor cells, 
tumor stroma, tumor vasculature and cellular signaling 
mechanisms that are aberrant in tumor tissue. They are 
now entering clinical trials and are expected to become 
attractive treatment options for malignancies.33, 34 Now, 
molecular-targeted therapies for ovarian cancer includ-
ing signal-transduction inhibitors and anti-angiogenesis 
have developed and several clinical trials have been 
performed for ovarian cancer.33, 35, 36 Unfortunately, 
molecular-targeted agent alone has been insufficient 
to improve the prognosis for advanced ovarian cancer. 
Therefore, molecular-targeted therapy should be carried 
out together with conventional cytotoxic agents. 
 Angiogenesis is a process critical for continuous 
tumor growth, invasion and metastasis. The new blood 
vessels created by angiogenesis from existing vascula-
ture (neovascularization) is a complex process regulated 
by a number of growth factors and cytokines, such as 
vascular endothelium growth factors (VEGFs), fibroblast 
growth factors, angiopoietin, platelet-derived growth 
factors (PDGFs), tumor necrosis factor-alpha and inter-
leukin 6 and 8 receptor pathways. The VEGF family and 
its receptors (VEGFRs) are one of the major pathways 
involved in tumor neovascularization. In ovarian cancer, 
overexpression of VEGF is often observed and has been 
associated with increased poor prognosis.37
 Bevacizumab is a recombinant, humanized, mono-
clonal immunoglobulin G1 antibody targeted at VEGF-
A. This antibody binds to and neutralizes all biologi-
cally active forms of VEGF-A (e.g., VEGF-A165) which 
suppresses growth of tumors and inhibits progression of 
metastatic disease.38, 39 Additionally, anti-VEGF drugs 
are thought to enhance the effects of chemotherapeutic 
agents by improving the structure and function (nor-
malization) of tumor vessels.40 Two phase III studies, 
Fig. 4. The amount of 
the extraction is sig-
nificantly greater in 
nonresponders than 
in responders (201.7 
± 92.5 versus 124.1 ± 
59.4 ng).
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the Gynecologic Oncology Group (GOG) 218 and the 
International Collaborative Group for Ovarian Neoplasia 
(ICON) 7, examined the combined effects with bevaci-
zumab and standard chemotherapy [paclitaxel (PTX) + 
carboplatin] in a first-line/adjuvant chemotherapy set-
ting.41, 42 The GOG218 trial was a 3-arm, double-blind, 
placebo-controlled, randomized, phase III study of 1873 
patients with macroscopic residual stage III or any stage 
IV ovarian, fallopian tube and peritoneal cancer.41 Pa-
tients who received bevacizumab (15 mg/kg) plus che-
motherapy with 16 cycles of maintenance bevacizumab 
had significantly longer progression-free survival (PFS) 
than those who received chemotherapy alone (median 
PFS, 14.1 versus 10.3 months). However, no significant 
difference in OS was observed. The rate of hypertension 
requiring medical therapy was higher in the chemother-
apy plus bevacizumab arm compared to chemotherapy 
alone, though gastrointestinal events above grade 2 
were observed in less than 3 % of patients. ICON7 had 
a similar design as a double-armed phase III study that 
enrolled 1528 patients with newly diagnosed high-risk 
stage I/IIA and stage III/IV ovarian, fallopian tube and 
peritoneal cancer, who were assigned randomly to che-
motherapy alone or chemotherapy plus bevacizumab (7.5 
mg/kg) with 12 cycles of maintenance bevacizumab.42 
Although the dose of bevacizumab used in this trial was 
half of that used in GOG218, it significantly prolonged 
PFS (median PFS, 17.4 versus 19.8 months). Hyperten-
sion of grade 2 or higher was observed more often in the 
bevacizumab arm (18 versus 2 % with chemotherapy 
alone). Among patients at high risk for progression (i.e., 
FIGO stage IV disease or stage III disease and > 1.0 cm 
of residual disease after debulking surgery), the median 
PFS (15.9 versus 10.5 months) and median OS (28.8 ver-
sus 36.6 months) were significantly longer in the bevaci-
zumab arm.  
  The Ovarian Cancer Education Awareness Network 
trial evaluated the efficacy of bevacizumab in com-
bination with carboplatin and gemcitabine in patients 
with recurrent, platinum-sensitive ovarian, primary 
peritoneal, or fallopian tube cancers after front-line, 
platinum-based therapy.43 A taotal of 484 patients were 
assigned randomly to a group administered 6 cycles of 
chemotherapy combined with bevacizumab (15 mg/kg) 
or to placebo followed by maintenance bevacizumab 
or placebo until their disease progressed or unaccept-
able toxicity developed. PFS for the bevacizumab arm 
was significantly longer than for the placebo arm (me-
dian PFS, 12.4 versus 8.4 months). Grade 3 or higher 
hypertension and proteinuria occurred more frequently 
in the bevacizumab arm. Another study, GOG213, is 
enrolling a targeted 660 patients with platinum-sensitive 
recurrent ovarian, primary peritoneal, or fallopian tube 
cancer. This randomized, phase III trial is comparing 
chemotherapy (PTX + carboplatin) every 3 weeks for 6 
to 8 cycles and chemotherapy plus bevacizumab (15 mg/
kg) with maintenance bevacizumab every 3 weeks. The 
surgical candidates among these patients will undergo 
secondary randomization to surgery or no surgery.
 Chemotherapy-induced activation of cell-survival 
pathways is observed frequently when conventional 
anticancer drugs are used, and targeting these survival 
signals will be invaluable in designing rational and novel 
combination therapies. A number of agents designed 
to inhibit the kinase components of those signaling 
pathways, including mitogen-activated protein kinase 
kinase (MEK)-extracellular signal-regulated kinase ki-
nase (ERK) and phosphatidylinositol 3'-kinase (PI3K)/
Akt, have been developed and clinically tested in cancer 
treatment, such as lung, breast cancer and melanoma.44, 
45 PTX functions by binding to intracellular beta-tubu-
lin, thus stabilizing microtubules. This action blocks 
normal cell-cycle progress when the mitotic metaphase 
and anaphase merge, preventing chromosome segrega-
tion and tumor-cell death. PTX also has the potential to 
modulate various signaling pathways, such as the MEK/
ERK signaling cascade and a PI3K–Akt pathway, which 
are proliferation and cell-survival pathways.46, 47, 48 Ac-
Fig. 5. The receiver operat-
ing characteristic (ROC) 
curve according to chemo-
response for TC (A), EP (B) 
and CPT-11/CDDP therapy 
(C). The optimal cut points 
are 80 for MDR-1, 90 for 
topo IIalpha and 200 for 
topo I by selecting the point 
on the ROC curve that maxi-
mized both sensitivity and specificity. CDDP, cisplatin; CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptoth-
ecin; EP, combination with etoposide and CDDP; MDR-1, multidrug-resistance-1; TC, combination with paclitaxel and carboplatin; 
topo, topoisomerase.
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tivating these pathways leads to phosphorylated Bc12 
antagonist of cell death and B-cell leukemia/lymphoma 
(Bcl)-2, and inhibits apoptosis. Amplified PI3K and 
activated Akt have been found in 30 to 40% of ovarian 
carcinomas and could represent the mechanism of drug 
resistance in patients with ovarian cancer.49
 Kawaguchi et al. reported that the additive effect of 
MEK inhibitor combined with PTX in ovarian cancer 
cell lines tested with a range of pMEK protein expression 
levels after PTX treatment. Enhanced PTX-induced cell 
death in the presence of MEK inhibitor may relate to sup-
pression of the survival-signaling function of the MEK–
ERK pathway, although the exact mechanism is unclear50 
(Fig. 5). The additive effect of PI3K inhibitor and PTX 
in all ovarian cancer cell lines was studied, regardless of 
the pAkt expression levels. Interestingly, upregulation of 
pAkt protein expression levels was seen after treating the 
cells with MEK inhibitor and PTX. Overexpression of 
activated Akt may decrease the sensitivity to the combi-
nation of MEK inhibitor and PTX. Inhibiting MEK and 
ERK upregulates Akt kinase activity.51 Inhibiting MEK 
pharmacologically does not only activate Akt, but also 
prolongs cell survival in normal cells. These findings 
suggest that simultaneously suppressing the MEK–ERK 
and PI3K–Akt pathways could dramatically intensify 
PTX-induced apoptosis in ovarian cancer cells. 
 Targeting these MEK–ERK and PI3K–Akt path-
ways may be important in treating ovarian cancer. 
Nonaka et al. treated ovarian cancer cell lines with 
CDDP and any of a PI3K inhibitor (LY294002), a MEK 
inhibitor (PD98059), or a MEK/ERK activator [phorbol 
12-myristate 13-acetate (PMA)], and assessed cell via-
bility, expression of MEK/ERK and PI3K/Akt, cell cycle 
distribution and apoptosis.52 CDDP and LY294002 had 
an additive effect on inhibiting cell growth, and CDDP 
and PD98059 had and antagonistic effect on cell growth 
in all cell lines (Fig. 6). In CDDP-resistant cells, CDDP 
and PMA dramatically suppressed the cell growth, up-
regulated the expression of phosphorylated ERK and 
cleaved caspase-9, down-regulated the expression of 
checkpoint kinases, and increased the proportion of 
cells in the synthesis-phase fraction and apoptotic cells. 
Those findings indicate that further study is warranted 
to determine the effectiveness of combination treatment 
with anticancer agents and molecular targeting therapy 
for platinum-resistant ovarian carcinoma.
 On the occasion of the use of the molecular target-
ed-agents, we must take care of the appearance of the 
unexpected adverse effect.53 Additionally, the cost-ef-
fectiveness should be an important issue. Because tailor 
made treatment based on the characteristic of the cancer 
cell is expected, translational research for biomarker is 
necessary. 
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